InvestorsHub Logo
Followers 6
Posts 876
Boards Moderated 0
Alias Born 08/06/2018

Re: None

Monday, 03/04/2019 6:20:02 AM

Monday, March 04, 2019 6:20:02 AM

Post# of 82910
In same article was some more validation that GRAS study is only good for one company, not all. Gives a good sense about how rigorous CVSI is:

"The company is one of a handful that is investing seriously in clinical trials to support its products on both sides of the Rx / non-Rx divide. CV has also taken a step that Tomc wishes more companies would follow: thorough toxicological studies.

“The only way you can argue that you’re not in violation of the Food Drug & Cosmetic Act is to do the toxicology and show that your formulation is safe,” said Tomc in an interview. CV has done extensive analysis on its formulas—which are derived from a well-characterized strain of food-grade hemp aerial plant parts.

“We have total confidence in our lab, which is fully GMP compliant, and audited by Eurofins (an international network of food, supplement, and agricultural safety testing labs). We have an adverse events reporting system in place, and we established No Observed Adverse Effects Levels (NOAEL) status for our products, per criteria in the Food, Drug & Cosmetic Act. This is the first formal toxicological work done on a hemp extract since 1981.”

Since hemp oil formulations vary greatly—each company is developing its own formulas, using different extraction methods, and including (or excluding) different cannabinoids—it is essential that each brand prove the safety of its own products.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVSI News